Predictive Presymptomatic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Predictive and Presymptomatic Testing Market Report is Segmented by Condition (Breast and Ovarian Cancer, Colorectal Cancer, Alzheimer's Disease, Multiple Endocrine Neoplasia Type - 2, and Haemochromatosis), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecast values are provided in terms of (USD) for all the above segments.

Predictive Presymptomatic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Predictive and Presymptomatic Testing Market Size

Predictive and Presymptomatic Testing Market Summary
Study Period 2021 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2021 - 2023
CAGR 8.40 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Predictive and Presymptomatic Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Predictive and Presymptomatic Testing Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Predictive and Presymptomatic Testing Market Analysis

The Predictive and Presymptomatic Testing Market is expected to register a CAGR of 8.4% during the forecast period.

The emergence of COVID-19 had its impact on the predictive and presymptomatic testing market as during the initial pandemic days there were strict lockdown restrictions imposed by the governments to curb the spread of COVID-19 which led to a decline in the number of predictive and presymptomatic testing. However, the market is recovering since the lockdown restrictions were lifted around the world and as the cases of COVID-19 are on the decline and the demand for predictive and presymptomatic tests is increasing. Hence, the studied market is expected to grow over the forecast period.

The market for predictive and presymptomatic testing is expected to grow over the forecast period due to factors such as the increasing prevalence of genetic disorders and rising demand for genetic counseling as they can be used to determine whether the patient has a hereditary disease-causing mutation or genetic disorders. Also, the rising awareness regarding genetic diseases among the global population is leading to an increase in demand for genetic counseling, thereby contributing to the growth of the market. For instance, the NHP data published in June 2021 stated that 300 million people are living with a rare disease worldwide and 70% that genetic rare diseases start in childhood. Similarly, according to the article published by Frontiers in 2021, in Japan, the rare hereditary disease prevalence was equivalent to less than 1 in 2,500 people. Also, as per the PHO statistics in 2021, about 10,000 diseases are monogenetic worldwide. Such a high prevalence of rare hereditary diseases and genetic disorders is expected to contribute to the demand for predictive and presymptomatic testing, thereby boosting the market growth.

Furthermore, the launch of new predictive and presymptomatic testing services across the globe, increasing investments, rising research and development activities, and adoption of key strategic initiatives by key market players are expected to contribute to the significant growth of the market. For instance, in September 2021, MedGenomeLabs launched its direct-to-consumer website, Genessense for consumers in India. The company offered two tests, Kardiogen and Curegen, through the Genessense website e-commerce platforms. Kardiogenis a polygenic risk score-based predictive test for coronary artery disease with a proven specificity of 90% for the Indian population. Thus, the above-mentioned factors are expected to drive the growth of the market during the forecast period. However, the high costs of tests and ethical issues in predictive testing are expected to restrain the development of the market.

Predictive and Presymptomatic Testing Industry Overview

The predictive and presymptomatic testing market is moderately competitive and is majorly comprised of local players in different countries. Some of the global players such as 23andMe, Abbott Laboratories, and Myriad Genetics hold a major share of the market. With the growing focus on genetic testing, it is expected that a few small to mid-sized companies will penetrate the market in the near future.

Predictive and Presymptomatic Testing Market Leaders

  1. 23andMe

  2. Abbott Laboratories

  3. Quest Diagnostics Inc.

  4. Myriad Genetics

  5. Positive Bioscience

  6. *Disclaimer: Major Players sorted in no particular order
Predictive and Presymptomatic Testing Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Predictive and Presymptomatic Testing Market News

  • In July 2022, GeneType partnered with Melbourne-based Siles Health to implement geneType Multi-risk test as part of their commitment to remain at the forefront of contemporary personalized patient health care.
  • In March 2022, NalageneticsPte. Ltd. received USD 12.6 million in a Series A round of financing. With the investment, the company is planning to expand its genetic testing solutions to implement predictive and presymptomatic testing for prevention geared toward chronic conditions in Asia.

Predictive and Presymptomatic Testing Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Genetic Disorders
    • 4.2.2 Increasing Demand for Genetic Counselling
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Tests
    • 4.3.2 Ethical Issues in Predictive Testing
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Condition
    • 5.1.1 Breast and Ovarian Cancer
    • 5.1.2 Colorectal Cancer
    • 5.1.3 Alzheimer's Disease
    • 5.1.4 Multiple Endocrine Neoplasia Type 2
    • 5.1.5 Haemochromatosis
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 23andMe
    • 6.1.2 Abbott Laboratories Inc.
    • 6.1.3 Quest Diagnostics Inc.
    • 6.1.4 Positive Bioscience
    • 6.1.5 Color Genomics
    • 6.1.6 Gene by Gene
    • 6.1.7 Mapmygenome
    • 6.1.8 Myriad Genetics
    • 6.1.9 BioAxis DNA Research Center Private Limited
    • 6.1.10 Direct Laboratory Services LLC
    • 6.1.11 Pathway Genomics Corporation
    • 6.1.12 Ambry Genetics Corporation
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Predictive and Presymptomatic Testing Industry Segmentation

As per the scope of the report, the predictive and presymptomatic test is a type of genetic test, which is used for the detection of gene mutations for disorders that appear in later stages of life. Predictive and presymptomatic testing finds immense potential among people, who have a family member with a genetic disorder. This test is particularly effective when no features of the disorder are visible at the time of testing. The Predictive and Presymptomatic Testing market is Segmented by Condition (Breast and Ovarian Cancer, Colorectal Cancer, Alzheimer's Disease, Multiple Endocrine Neoplasia Type - 2, and Haemochromatosis), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Condition Breast and Ovarian Cancer
Colorectal Cancer
Alzheimer's Disease
Multiple Endocrine Neoplasia Type 2
Haemochromatosis
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Predictive and Presymptomatic Testing Market Research FAQs

What is the current Predictive and Presymptomatic Testing Market size?

The Predictive and Presymptomatic Testing Market is projected to register a CAGR of 8.4% during the forecast period (2025-2030)

Who are the key players in Predictive and Presymptomatic Testing Market?

23andMe, Abbott Laboratories, Quest Diagnostics Inc., Myriad Genetics and Positive Bioscience are the major companies operating in the Predictive and Presymptomatic Testing Market.

Which is the fastest growing region in Predictive and Presymptomatic Testing Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Predictive and Presymptomatic Testing Market?

In 2025, the North America accounts for the largest market share in Predictive and Presymptomatic Testing Market.

What years does this Predictive and Presymptomatic Testing Market cover?

The report covers the Predictive and Presymptomatic Testing Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Predictive and Presymptomatic Testing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Property and Casualty Insurance in Netherlands Industry Report

Statistics for the 2025 Predictive and Presymptomatic Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Predictive and Presymptomatic Testing analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.